Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT02083510

Apolipoprotein CIII Reduction Via Colchicine

A Translational Study to Understand the Mechanism of Apolipoprotein CIII Reduction Via Colchicine

Sponsor: Scripps Translational Science Institute

Conditions Gout Hypertriglyceridemia Pericarditis

Interventions Colchicine

Updated 6 times since 2017 Last updated: May 28, 2014 Started: Feb 28, 2014 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Gout and Hypertriglyceridemia, this trial is completed. The trial is conducted by Scripps Translational Science Institute and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Scripps Translational Science Institute

Data source: Scripps Translational Science Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• La Jolla, United States